Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
WALTHAM, Mass. --(BUSINESS WIRE)--May 25, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
View HTML
Toggle Summary ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review
PDUFA Date is November 28, 2022 WALTHAM, Mass. --(BUSINESS WIRE)--May 23, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has accepted and filed the
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference
WALTHAM, Mass. --(BUSINESS WIRE)--May 10, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller , Chief Financial Officer, will present at the upcoming H.C.
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results
Submitted BLA for Mirvetuximab Soravtansine Monotherapy to FDA Under Accelerated Approval Pathway; Commercial Preparations Underway Presented Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer in Plenary Session at SGO Annual Meeting; Additional   Efficacy and
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--May 2, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on April 29, 2022 , the compensation committee of the Company’s Board of Directors approved grants of
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its First Quarter 2022 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 21, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 6, 2022 to discuss its first
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 1, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on March 31, 2022 , the compensation committee of the Company’s Board of Directors approved grants of
View HTML
Toggle Summary ImmunoGen Announces Webcast of Panel Discussion at Upcoming Canaccord Genuity Horizons in Oncology Virtual Conference
WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 31, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Dr. Anna Berkenblit , Chief Medical Officer, will participate in the Reshaping Ovarian Cancer panel
View HTML
Toggle Summary ImmunoGen Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer
Submission Based on Positive Results from Pivotal Phase 3 SORAYA Trial WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 29, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it has submitted a Biologics
View HTML
Toggle Summary ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting
Trial Met Primary Endpoint with Confirmed Objective Response Rate of 32.4%, including 5 Complete Responses; Updated Median Duration of Response of 6.9 Months Mirvetuximab Demonstrated Meaningful Anti-Tumor Activity, Consistent Safety, and Favorable Tolerability in FRα-High Platinum-Resistant
View HTML